Nvidia, Eli Lilly plan AI drug innovation lab
Digest more
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
Asianet Newsable on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
Pfizer’s CEO Albert Bourla is looking to initiate about 10 late-stage trials of the company’s new obesity drugs.
InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...
An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...
Ebrahimi is a scientific leader at GSK. Mrksich is the Henry Wade Rogers professor at Northwestern University, where he is developing the MegaMolecule technology for creating multifunctional ...
La Jolla scientists are stepping into a national push to get new medicines from lab bench to bedside faster. The project, known as PREDICTS, has been awarded up to $31.7 million from a federal health ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many ...
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...
The Drug Discovery and Development program provides in-depth exposure to the multiple elements involved in the discovery and development of marketed drugs. It provides the rigorous scientific ...
The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback